Trial Information

Official Title: Somatuline® Depot (Lanreotide) Injection for Acromegaly (SODA): A Post-marketing Observational Study

Summary

To assess the safety and effectiveness of Somatuline® Depot (lanreotide) Injection when administered by a health care professional (HCP), the patient, the patient's partner or parent/guardian as part of their routine acromegaly care.

Phase: N/A

Sponsor: Ipsen

Overall Contacts:

Ipsen Central Contact

clinical.trials@ipsen.com